BACKGROUND: The brain endogenous cannabinoid system modulates reward and craving pathways and consequently may affect body weight. A naturally occurring missense polymorphism in the gene encoding fatty acid amide hydrolase (FAAH), the primary enzyme for inactivation of endocannabinoids, is associated with problem drug use. AIMS: To investigate the relationship between the FAAH cDNA 385 A/A (P129T) polymorphism and overweight disorders in subjects of multiple ethnic backgrounds attending a medical screening clinic. SUBJECTS: A total of 2667 subjects of white, black and Asian ancestry were genotyped and stratified by a standardized clinicbased assessment of body mass index (BMI, weight in kilograms/(height in meters) 2 or kg/m 2 ). METHODS: Subjects were genotyped for the FAAH cDNA 385 C-A polymorphism using allele-specific oligonucleotide hybridization methods by investigators blinded to all clinical information. BMI was calculated based on exact clinical measurements and World Health Organization ranges were used to stratify subjects. Statistical methods included the Fisher exact test, Mann-Whitney U-test and multivariable logistic regression analysis. RESULTS: The homozygous FAAH 385 A/A genotype was significantly associated with overweight and obesity in white subjects (P ¼ 0.005) and in black subjects (P ¼ 0.05) but not in a small group of Asians. The median BMI for all subjects was significantly greater in the FAAH 385 A/A genotype group compared to heterozygote and wild-type groups (P ¼ 0.0001). In white subjects, there was an increasing frequency of the FAAH 385 A/A genotype with increasing BMI categories of overweight (P ¼ 0.02) and obese (P ¼ 0.006) with the same trend in black subjects. CONCLUSIONS: These results suggest a role for the FAAH 385 A/A missense polymorphism as an endocannabinoid risk factor in overweight/obesity and may provide indirect evidence to support cannabinoid antagonist treatment strategies in overweight disorders.
Introduction
Overweight and obesity are major public health problems that are estimated to affect two-thirds (465%) of the American population and have been identified as risk factors for many common diseases. 1 Predisposition to obesity is a complex process influenced by the interaction of multiple genetic variants, environmental factors and developmental processes. 2 Herbal Cannabis sativa (marijuana) has been known for centuries to have many medicinal and psychoactive effects in humans including robust increases in appetite and body weight. 3 However, the molecular mechanisms underlying cannabinoid neurobiological effects have been only recently revealed. 4, 5 In mammals, the endogenous cannabinoid system mediates cannabinoid-like signaling in the nervous system and is positioned both anatomically and functionally [6] [7] [8] to be an important endogenous modulator of normal human brain activity and, consequently, of human behavior. The principal inactivating enzyme of endogenous cannabinoid receptor ligands is fatty acid amide hydrolase (FAAH), which has been identified as the catabolic enzyme capable of inactivating most of the endocannabinoids. 9, 10 Gene disruption experiments in animals have shown that FAAH controls both the amplitude and duration of endocannabinoid behavioral effects in mammals. 11 Moreover, the pharmacological effects of many endocannabinoids appear to be regulated by FAAH activity in vivo, 12 suggesting that FAAH has the potential to be a significant modulating enzyme for human behavior. In a population study of the gene encoding FAAH, we identified a missense polymorphism (cDNA 385 C-A) that predicts a substitution of threonine for a highly conserved proline residue at amino-acid position 129 (P129T) and is significantly associated with problem drug use or abuse. 13 By logical extension, we decided to study whether this FAAH variant could be related to other reward disorders such as endocannabinoid-induced appetite stimulation 14 and overweight disorders.
Considering the evidence that the endogenous cannabinoid system plays a significant role in both hedonic and metabolic aspects of feeding behavior and body weight, 15, 16 we decided to investigate the question of whether homozygosity for this FAAH missense polymorphism is also associated with overweight and obesity. Since the same or similar reward and reinforcement pathways in the brain likely modulate natural rewards such as food and sweets as well as artificial rewards of illicit drugs, it seemed reasonable that similar risk factors could contribute to vulnerability in both disorders. Recent biochemical evidence of reduced cellular expression and activity of the P129T variant of human FAAH also provides a functional link between defects in the endocannabinoid system and problem drug use. 17 The present study examines the relationship of overweight disorders to the FAAH 385 A/A (P129T) homozygous polymorphism in white subjects, black subjects and Asians, since we found different polymorphism frequencies in these racial groups suggesting possible differential effects on overweight and obesity.
Methods
The subjects included in this study gave informed consent and the study was approved by the Scripps Human Subjects Committee (institutional review board, IRB). Each subject, identified to the investigators only by a number, completed a comprehensive health appraisal questionnaire that was linked to the subject's DNA sample and demographic information. All experiments were conducted in compliance with relevant laws and institutional guidelines. Subjects with a history of problem drug use or abuse, based on self-reported answers on the questionnaire, were excluded from the current study. Subjects with a self-reported race/ethnicity of 'hispanic' were also excluded because this group is defined by common language rather than common ancestry, and in Southern California, represents a population of greater mixed racial origin than white and black populations. White subjects were self-reported to be of European ancestry. Black subjects were US residents of African origin (African-American). Asians were a mixture of several Asian regional origins. A total of 1688 white subjects were selected randomly from the remaining group of eligible subjects for genotyping of the FAAH 385 locus. All eligible black subjects (n ¼ 614) and all eligible Asian subjects (n ¼ 365) also underwent FAAH genotyping. Genotyping for the FAAH cDNA 385 C-A polymorphism was performed using the previously described allele-specific oligonucleotide hybridization technique. 18 Those performing the assays were blinded to subjects' clinical information, including height and weight. Body mass index (BMI, weight in kilograms/(height in meters) 2 or kg/m 2 ) was calculated for each subject based on exact height and weight measurements by experienced nursing staff at the time of blood sample collection. World Health Organization (WHO) BMI ranges were used to categorize subjects as normal weight (18. 19,20
The current recommendations for Asian BMI ranges 19 were used in this study. Statistical analyses included comparison of the median BMI by genotype in subjects homozygous for the FAAH 385 A/A polymorphism compared with subjects with either the FAAH 385 C/A or 385 C/C genotype) using the MannWhitney U-test. Differences in the frequency of FAAH 385 A/A by weight category were tested for each ethnic group and by sex using the Fisher exact test. Results were obtained using weight categories defined (1) as normal weight vs overweight and obese and (2) by using BMI as a continuous variable vs FAAH genotype. Multivariable logistic regression was used to assess the relationship between genotype and weight category (normal weight vs overweight/obese) among all 2667 subjects in the study controlling for multiple potential confounding variables including age, race, sex, and selected interaction terms. The statistical analysis in this study was based on current knowledge that FAAH metabolizes only neuromodulatory endocannabinoids 9 and our specific predetermined hypothesis that because the FAAH 385A/A homozygous polymorphism (P129T FAAH variant) results in decreased FAAH activity and expression, 17 the mutant genotype would be positively associated with overweight and obesity due to increased endocannabinoid system signaling. Based on this rigorous prospective hypothesis, one-sided P-value tests were used and P-values of o0.05 were considered statistically significant.
Results
The study population was 46.4% male with a mean age (7s.d.) of 57.2 (714.1) y. The overall frequency of FAAH 385 A/A homozygotes in the study population was 3.7% in white subjects, 10.8% in black subjects and 3.6% in Asians. When subjects were stratified by WHO BMI categories, there was a significantly higher proportion of individuals with the FAAH 385 A/A genotype in the overweight/obese group when compared with the normal weight group among both white (P ¼ 0.005) and black subjects (P ¼ 0.05) ( (Figure 1 ). The same trend by BMI categories was observed in a smaller sample of black subjects, but was statistically significant only for the obese group (Figure 1 ). In the small group of Asian subjects included in this study, the frequency of the FAAH 385 A/A polymorphism was actually slightly greater in normal BMI subjects rather than the overweight/obese individuals as seen in white and black subjects (Table 1) .
When the data for subjects of all ethnicities and both sexes were pooled, the median BMI for subjects with the FAAH 385 A/A genotype was found to be significantly higher than the median BMI of subjects with the FAAH 385 C/A or C/C genotype (Po0.0001, Table 2 ).
Discussion
Normal cannabinoid-like signaling in the human brain is now known to be mediated through the endogenous cannabinoid system, 21 a signaling pathway that includes the cannabinoid 1 and 2 receptors, a growing family of lipoamino-acid transmitter ligands, the 'endocannabinoids', and their principal inactivating enzyme, FAAH. 8 Both exogenous cannabinoids such as delta-9-tetrahydrocannabinol, the principal psychoactive ingredient of marijuana, and endogenous cannabinoids such as anandamide and 2-arachidonylglycerol may engage and activate the cannabinoid receptor 1 (CB1) that is highly expressed in many brain synaptic terminals. 22, 23 Endocannabinoids are synthesized and released at the postsynaptic membrane and act backwards on CB1 receptors in the presynaptic membrane to inhibit or downregulate the release of many classical neurotransmitters. [24] [25] [26] The activation of CB1 receptors by endocannabinoids in specific neuronal circuits typically produces downregulation of neurotransmitter release, for example, in the major inhibitory transmitter, gamma amino butyric acid, or the major excitatory transmitter, glutamate, FAAH polymorphism and overweight disorders JC Sipe et al in addition to many other neurotransmitters. [27] [28] [29] In turn, this may result in modulation of inhibitory or excitatory activity in specific brain circuits with observable mammalian neurobehavioral changes. 29, 30 Accumulating evidence indicates that the endogenous cannabinoid system is an essential homeostatic regulator of energy balance and weight via central appetite-stimulating mechanisms as well as peripheral lipogenesis. 31 Moreover, leptin, the primary peripheral signal that modulates hypothalamic effects on food intake, is involved in regulating endocannabinoid levels in the hypothalamus, which may in turn activate CB1 receptors to influence food intake and body weight. 32 A recent review has summarized the evidence for the endogenous cannabinoid system as a modulator of feeding behavior, and ultimately, as one of the major influences on body weight. 15 As the actions of endocannabinoids and FAAH are specifically exerted in the addiction/ reward pathway including the nucleus accumbens and in memory areas of the hippocampus, the hedonic and memory aspects for rewards of eating may be increased and may thus influence the severity of diet-induced obesity. 16 By acting in these neural circuits, endocannabinoids may drive the appetite for palatable food as suggested in recent animal studies. 33 An experimental study of the treatment of dietinduced obesity in animals recently demonstrated the antiobesity effect of the specific CB1 receptor antagonist, SR141716A, that blocks endocannabinoid activation of CB1 receptors, and this strategy appears to have potential in humans as an obesity treatment. 34 In a previous study, we showed that the FAAH 385 A/A missense polymorphism was very significantly associated with problem drug use and abuse but not alcohol or tobacco abuse. 13 In the present study, we considered that in similar reward and craving brain circuits modulated by endocannabinoids in drug abuse, the effects of the FAAH 385 A/A polymorphism could result in the upregulation of natural reward behaviors such as consumption of sweets and palatable food associated with overweight and obesity. Since any genetic risk or prevention factors that may be identified in overweight and obesity could be useful in promoting treatment and prevention strategies, we examined whether the FAAH 385 A/ A polymorphism, which may result in decreased endocannabinoid inactivation, is a risk factor for overweight and obesity. The summary of the univariate analysis in Table 1 shows a significant association of the FAAH 385 A/A genotype with overweight and obesity in white and black individuals compared to normal BMI status individuals and a greater than two-fold increased prevalence of homozygous variant subjects in the overweight/obese groups. It is noteworthy that when BMI was evaluated as a continuous variable in all subjects, the median BMI was significantly higher in subjects with the 385 A/A genotype compared to the median BMI or the other subjects ( Table 2 ). The small Asian population of mixed regional origin in this study did not have enough statistical power to demonstrate significance or there may be regional phenotypic or genotypic factors other than FAAH influencing obesity in Asians.
What mechanisms involving the endogenous cannabinoid system could play a role as risk factors in overweight and obesity? Under normal circumstances, brain endocannabinoid signaling may exert tonic control on the levels of certain neurotransmitters in specific neuronal circuits. Among the most well studied, the mesolimbic addiction and reward/craving circuit including the medial forebrain bundle projections to the nucleus accumbens shows a high correlation of CB1 receptor density and FAAH enzyme expression. 35 This anatomical convergence of CB1 receptors and FAAH enzyme activity capable of regulating endocannabinoid tone supports the notion that FAAH is positioned for constitutive regulation of endocannabinoid levels locally 12 that could influence reward and craving behaviors through the relevant neuronal circuitry. Based on biochemical evidence in our previous study that the FAAH 385 A/A missense polymorphism may code for functionally deficient protein, 13 we recently found that subjects with this polymorphism have approximately half the FAAH enzymatic activity and protein expression when compared with wild-type subjects. 17 This provides a link between the functional consequences of this polymorphism and the present epidemiological study indicating that the FAAH 385 A/A (P129T) polymorphism may be one risk factor for susceptibility to overweight and obesity. Collectively, the current findings support the concept that abnormal brain endocannabinoid signaling may be a significant risk factor for both drug-induced and natural reward disorders such as appetite stimulation for palatable food. These data suggest an expanded view of reward/craving behaviors as a consequence of the naturally occurring FAAH 385 A/A missense polymorphism that may range from drug abuse to natural rewards in vulnerable individuals. Identification of individuals homozygous for this polymorphism may disclose those at greater risk for overweight and obesity and may support the therapeutic use of cannabinoid antagonist strategies. FAAH polymorphism and overweight disorders JC Sipe et al
